Clinical Trial

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is the first-in-human of ASKC202, which is an open-label, non-randomized, multicenter study with a dose escalation phase and a dose expansion phase.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-03-23; most recent amendment 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2023-03-03
Trial Details
NCT Number NCT05306132
Lead Sponsor Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 150 participants
Start Date 2022-08-08
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-23